Pasithea Therapeutics Expands Clinical Trial Locations
Pasithea Therapeutics Corp. (NASDAQ: KTTA) continues to make strides in the clinical research space by opening new trial sites in Eastern Europe. This move allows the company to enhance its recruiting capabilities for the PAS-004 Phase 1 trial, aimed at treating neurofibromatosis type 1 (NF1) and certain cancer indications. This trial is particularly critical as it focuses on a next-generation macrocyclic MEK inhibitor designed to tackle challenges in existing therapies.
New Clinical Trial Sites Established
With the addition of three clinical trial sites in Romania and Bulgaria, Pasithea is taking significant steps to expedite patient recruitment. These new sites are part of a broader strategy that includes existing sites in the United States. In total, the clinical trial will proceed across several locations, thus diversifying the participant pool and increasing the robustness of trial data collected.
Initial Dosing and Patient Recruitment Updates
As part of the PAS-004 study, Pasithea has successfully completed initial dosing of three patients with the 15mg capsule formulation in Cohort 4A. At this juncture, recruitment for Cohort 4B, which involves the 4mg tablet formulation, is ongoing. The company anticipates releasing interim safety and pharmacokinetic (PK) data for both cohorts soon, providing insights into the drug’s effectiveness and safety profile.
Expert Insights on Patient Care
Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics, expressed enthusiasm about the collaboration with Arensia in Eastern Europe. He noted that this initiative not only enhances the trial's geographical scope but also allows engagement with patients whose tumor types may respond better to single-agent MEK therapy or have experienced setbacks with older generation MEK inhibitors. This strategic focus aims to optimize patient outcomes and improve treatment efficacy.
Understanding PAS-004 and Its Potential Impact
Pasithea's ongoing Phase 1 clinical trial employs a multi-center, open-label design with a dose-escalation methodology. This method is tailored to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of PAS-004 specifically for patients presenting with MAPK pathway-driven advanced solid tumors. The thoroughness of this approach aims to ensure rigorous evaluation, aligning with the company’s commitment to quality and safety in drug development.
Focus on Neurological Disorders and Beyond
Beyond its work with PAS-004, Pasithea Therapeutics is dedicated to addressing the unmet medical needs in central nervous system (CNS) disorders and RASopathies. Their team of experts brings deep knowledge in neuroscience and drug development, focusing on creating new treatments for conditions such as Amyotrophic Lateral Sclerosis (ALS) and NF1. The commitment to innovation is clear as they strive to deliver effective therapies to patients facing debilitating health challenges.
Frequently Asked Questions
What is PAS-004?
PAS-004 is a next-generation macrocyclic MEK inhibitor being developed by Pasithea Therapeutics for the treatment of neurofibromatosis type 1 and other cancer indications.
Where are the new clinical trial sites located?
The new clinical trial sites are located in Romania and Bulgaria, augmenting the existing sites in the United States.
What are the main goals of the PAS-004 trial?
The trial aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of PAS-004 in patients with specific advanced solid tumors.
Who is the CEO of Pasithea Therapeutics?
Dr. Tiago Reis Marques is the Chief Executive Officer of Pasithea Therapeutics, steering the company towards innovative solutions in biotechnology.
How can I contact Pasithea Therapeutics?
Contact can be made through Patrick Gaynes in Corporate Communications via email at pgaynes@pasithea.com for more information or inquiries.
